Previous reports have demonstrated that chymase inhibitor attenuates inflammation and fibrosis without influencing blood glucose and lipid levels and blood pressure in animal models of diabetes, hyperlipidemia, and hypertension, respectively (Inoue et al., 2009; Takai et al., 2014; Zhang et al., 2016). Here, CMA1 is linked to Hypertension.